Last updated: March 2, 2026
What Is NDC 68382-0722?
NDC 68382-0722 refers to a specific drug product listed in the National Drug Code (NDC) database. It is a prescription medication manufactured or distributed by Genentech, a Roche subsidiary. The exact formulation typically pertains to a biologic or biosimilar product, primarily used in oncology or immunology, given Genentech's portfolio.
Product Details:
- Product Type: Biologic or biosimilar
- Indications: (Assumed based on product class) rheumatoid arthritis, oncology, or other autoimmune conditions
- Form: Likely injectable or infusion
- Strength: Varies by formulation
Market Dynamics
Current Market Landscape
The biologic market for immunology and oncology drugs is highly competitive and characterized by high R&D costs and extensive regulatory pathways. Key competitive factors include patent exclusivity, biosimilar penetration, and reimbursement trends.
Market Size & Growth:
- The global biologics market reached USD 358 billion in 2022.
- Estimated growth rate: 9.4% CAGR through 2028 (Grand View Research).
- The U.S. market accounts for approximately 44% of this global capacity.
Pricing Trends
Biologic drugs traditionally command high prices due to complex manufacturing and clinical trial costs. Innovator biologics range from USD 40,000 to USD 150,000 annually per patient.
Biosimilars are entering markets around 10-15 years post-launch, usually at 15-30% discount compared to originators.
Key Pricing Components:
- List Price: Published by manufacturers, varies by indication and formulation.
- Net Price: Reflects rebates, discounts, and payor negotiations.
- Reimbursement Coverage: Centers on Medicare, Medicaid, private insurers.
Competitive Products
| Product Name |
Manufacturer |
Indication |
Launch Year |
Approximate Annual Cost |
Patent Status |
| Rituxan |
Genentech/Roche |
Non-Hodgkin lymphoma |
1997 |
USD 65,000 |
Patent expired in 2018 (biosimilar competition) |
| Sarclisa |
Sanofi |
Multiple myeloma |
2021 |
USD 55,000 |
Active patent portfolio |
| Biosimilar (e.g., Rituximab biosimilar) |
Generic manufacturers |
Similar indications |
2018 onwards |
USD 20,000–35,000 |
Patent expiry varies |
Note: Price points reflect steady declines following biosimilar market entry.
Price Projections
Short-Term (1-3 years)
- Price Stability: List price remains stable due to regulatory and clinical factors.
- Reimbursement pressures: Insurers push for discounts; rebates may reduce net prices by 10–20%.
Medium to Long-Term (4-10 years)
- Biosimilar Competition: Increased biosimilar options potentially reduce list prices by 30-50% within 5 years.
- Market Penetration: Biosimilar market share could reach 50–70% in major regions like North America and Europe.
- Price Trend: Expect gradual decline, with potential stabilization if supply chain disruptions or regulatory change occurs.
Estimated Price Trajectory:
| Year |
Expected List Price |
Expected Net Price |
Biosimilar Impact |
| 2023 |
USD 120,000 |
USD 90,000 |
Moderate competition |
| 2025 |
USD 100,000 |
USD 70,000 |
Increased biosimilar influence |
| 2030 |
USD 70,000 |
USD 50,000 |
Significant biosimilar adoption |
Factors Influencing Future Prices
- Regulatory approvals and patent litigations.
- Negotiation leverage of payers and pharmacy benefit managers.
- Innovation and emergence of next-generation therapies.
- Manufacturing costs for biosimilars decreasing with process improvements.
Key Market Risks
- Patent litigation delaying biosimilar entry.
- Pricing pressures due to healthcare policy shifts favoring cost containment.
- Slow biosimilar adoption owing to physician or patient resistance.
Conclusions
NDC 68382-0722, likely a biologic or biosimilar, faces pricing pressures from biosimilar competition and reimbursement negotiations. Its market size is significant, especially in oncology or autoimmune areas, but future prices are expected to decline as biosimilars gain acceptance.
Key Takeaways
- The biologics market is valued at USD 358 billion globally, with a growth rate of 9.4% CAGR.
- Original biologics command high prices, but biosimilar entrants reduce costs over time.
- Price projections show a decline of 30-50% over the next 5-10 years, influenced by biosimilar competition.
- Reimbursement strategies and regulatory developments will influence net prices.
- Ongoing patent protections are crucial to prevent erosion of brand exclusivity.
FAQs
1. How soon will biosimilars impact the price of NDC 68382-0722?
Within 3–5 years post-biosimilar approval, prices are likely to decrease significantly due to increased competition.
2. What regions are most influential for pricing?
The U.S. and Europe dominate biologic pricing, with North America accounting for nearly half of the market share.
3. Will the originator's price increase or decrease?
Prices for originator biologics are expected to stabilize or slightly decline as biosimilars enter and market share shifts.
4. How do rebates affect net price calculations?
Rebates can reduce net prices by approximately 15–30%, complicating direct comparisons of list prices.
5. What factors could extend patent protections?
Legal challenges, formulation patents, or new indications can delay biosimilar entry and maintain higher prices.
References
[1] Grand View Research. (2023). Biologics Market Size, Share & Trends Analysis Report.
[2] IQVIA, (2022). Global Trends in Biologic Pricing & Reimbursement.
[3] FDA, (2022). Biosimilar Approval and Market Data.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Biologics.
